Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib + Irinotecan in 2nd Line KRAS/BRAF Mutated CRC
NCT01116271Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2010
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in colorectal cancer (CRC), sponsored by AstraZeneca. Started Apr 2010; status: completed.
02
Drugs
selumetinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01116271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01116271.